Alkermes Aims for Growth with Neuroscience Focus

An update from Alkermes ( (ALKS) ) is now available.

Alkermes is poised for growth in 2024 with its neuroscience focus, driven by four core products that have generated over $1 billion in revenue. The company aims to sustain profitability and significant cash generation, leveraging its robust drug development capabilities and expanding its neuroscience pipeline. Alkermes plans to advance its orexin 2 receptor agonist program, explore external opportunities, and focus on capital allocation, potentially returning capital to shareholders.

For a thorough assessment of ALKS stock, go to TipRanks’ Stock Analysis page.